Thanks to recent advances in genome sequencing, cancer panel tests have emerged as useful tools for making diagnoses, predicting prognoses, and determining treatment strategies in rare cancers.[6] In the present case, we found mutations in NOTCH2, NCOA4, PTEN, EPHA3, and KMT2D, whereas TP53 mutation was not detected, which is consistent with the negative or only weakly positive staining for p53.[3] FATHMM-XF analysis predicted the single nucleotide mutations detected in NCOA4, PTEN, and EPHA3 to be pathogenic (Table 2). This evidence concerns the gene NCOA4 and cancer.